RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $5.29 Consensus PT from Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has been assigned a consensus recommendation of “Hold” from the nine ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $4.00.

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of RAPT Therapeutics in a report on Monday, March 10th.

RAPT Therapeutics Stock Down 7.1 %

Shares of RAPT opened at $1.45 on Thursday. The business has a 50-day simple moving average of $1.19 and a two-hundred day simple moving average of $1.47. RAPT Therapeutics has a 12-month low of $0.79 and a 12-month high of $9.65. The stock has a market cap of $191.41 million, a PE ratio of -0.52 and a beta of -0.31.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.69). On average, equities research analysts expect that RAPT Therapeutics will post -2.14 EPS for the current year.

Hedge Funds Weigh In On RAPT Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Trustees of Columbia University in the City of New York bought a new stake in shares of RAPT Therapeutics in the 4th quarter valued at about $116,000. Shay Capital LLC bought a new stake in RAPT Therapeutics in the 4th quarter worth approximately $81,000. RTW Investments LP purchased a new stake in shares of RAPT Therapeutics during the 4th quarter valued at about $18,587,000. Redmile Group LLC raised its holdings in RAPT Therapeutics by 1,183.4% in the 4th quarter. Redmile Group LLC now owns 6,475,317 shares of the company’s stock worth $10,231,000 after purchasing an additional 5,970,785 shares during the period. Finally, Nuveen Asset Management LLC increased its stake in shares of RAPT Therapeutics by 50.5% in the fourth quarter. Nuveen Asset Management LLC now owns 116,925 shares of the company’s stock worth $185,000 after purchasing an additional 39,216 shares in the last quarter. Hedge funds and other institutional investors own 99.09% of the company’s stock.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.